Immuron says FY25 global sales exceed projection, up 49% over prior year

Immuron (IMRN) is pleased to announce continued sales growth of Travelan, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract. Flavio Palumbo, Chief Commercial Officer, said, “Immuron has exceeded sales projections and achieved record FY25 sales of A$7.3 million, with growth just shy of 50% on last year. In FY25, we set out to make Travelan the must-have travel essential for consumers and retailers. This is a fantastic result, supporting our clear growth strategy. Australia, on the back of increased consumer engagement and a clear pharmacy visibility program, achieved annual sales of A$5.2 million, growth of 40% on last year. Travelan is now one of the fastest growing brands in pharmacy in Australia. Our North American business continues to produce record results with strong USA sales to Amazon with improved, more targeted communication focused on the benefits of Travelan driving more users into the brand. This, together with establishing good distribution of Travelan in Canada, resulted in North American sales of A$2 million, growth of 76% on last year. We have achieved record Travelan sales in all markets. In FY26, we will invest to grow in North America while continuing the momentum in Australia.”